secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001558370-25-010850
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO completes Phase 2b enrollment for KPI-012; cash runway into Q1 2026
----------------------------------------------------------------------------

- Net loss $11.2M ($1.71/share) for Q2 2025 vs $9.6M ($3.16) in Q2 2024.
- Cash $31.9M as of June 30; expected to fund operations into Q1 2026.
- Phase 2b CHASE trial enrolled 79 patients; topline data expected end of September 2025.
- R&D expenses $6.2M in Q2, up 17% YoY due to KPI-012 development costs.
- Interim CEO says positive results could support a BLA submission to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/0001558370-25-010850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer